Skip to main content

Table 2 Demographic, clinical, histological, molecular and treatment characteristics of patients and analysis of groups homogeneity (test Pearson Khi2)

From: Concurrent chemoradiotherapy in adjuvant treatment of breast cancer

Characteristic Group A [n = 110] No (%) Group B [n = 134] No (%) p value
Age
   <40 31 (28.2%) 23 (17.2%) 0.039
   ≥40 79 (71.8%) 111 (82.8%)  
Menopausal status
   No 75 (72.8%) 77 (62.1%) 0.087
   Yes 28 (27.2%) 47 (37.9%)  
Side
   Right 48 (43.6%) 71 (53%) 0.146
   Left 62 (56.4%) 63 (47%)  
Surgery
   Mastectomy (Patey or Halsted) 89 (80.9%) 116 (86.6%) 0.23
   Conservative 21 (19.1%) 18 (13.4%)  
Histology
   DIC 99 (94,3%) 120 (90,9%) 0.33
   LIC 6 (5.7%) 12 (9.1%)  
SBR
   I 6 (5.7%) 11 (8.5%) 0.567
   II 69 (65.1%) 87 (66.9%)  
   III 31 (29.2%) 32 (24.6%)  
Hormonal receptors
ER
   Positive 77 (72%) 97 (73.5%) 0.793
   Negative 30 (28%) 35 (26.5%)  
PR
   Positive 61 (57.5%) 82 (62.1%) 0.474
   Negative 45 (42.5%) 50 (37.9%)  
Tumour
   pT1 16 (14.7%) 19 (14.5%) 0.732
   pT2 62 (56.9%) 76 (58%)  
   pT3 28 (25.7%) 29 (22.1%)  
   pT4 3 (2.8%) 7 (5.3%)  
pN, axillary
   pN0 20 (18.2%) 40 (29.9%) 0.001
   pN1 30 (27.3%) 42 (31.3%)  
   pN2 31 (28.2%) 42 (31.3%)  
   pN3 29 (26.4%) 10 (7.5%)  
Breast/thoracic wall irradiation
   Yes 109 (99.1%) 124 (92.5%) 0.014
   No 1 (0.9%) 10 (7.5%)  
Prophylactic supraclavicular fossa radiotherapy
   Yes 104 (94.5%) 127 (94.8%) 0.936
   No 6 (5.5%) 7 (5.2%)  
Internal mammary radiotherapy
   Yes 105 (95.5%) 128 (95.5%) 0.98
   No 5 (4.5%) 6 (4.5%)  
Axillary radiotherapy
   Yes 18 (16.4%) 31 (23.1%) 0.189
   No 92 (83.6%) 103 (76.9%)  
  1. SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptor